Your browser doesn't support javascript.
loading
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).
Levy, Benjamin; Barlesi, Fabrice; Paz-Ares, Luis; Bennouna, Jaafar; Erman, Mustafa; Felip, Enriqueta; Isla, Dolores; Ryun Kim, Hye; Kim, Sang-We; Madelaine, Jeannick; Molinier, Olivier; Özgüroglu, Mustafa; Rodríguez Abreu, Delvys; Adeniji, Abidemi; Lorence, Robert M; Voccia, Isabelle; Chisamore, Michael J; Riess, Jonathan W.
Afiliación
  • Levy B; Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Washington, DC, USA. Electronic address: blevy11@jhmi.edu.
  • Barlesi F; Aix Marseille University, CNRS, INSERM, CRCM, Assistance Publique Hôpitaux de Marseille, Marseille, France; Gustave Roussy Cancer Campus, Villejuif, France.
  • Paz-Ares L; Department of Medical Oncology, University Hospital 12 De Octubre, Madrid, Spain.
  • Bennouna J; Department of Pneumology, Thoracic Oncology, University Hospital - Nantes, Nantes, France.
  • Erman M; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Felip E; Medical Oncology Department, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Isla D; Department of Medical Oncology, University Hospital Lozano Blesa, Zaragoza, Spain.
  • Ryun Kim H; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim SW; Department of Oncology, Asan Medical Center, Seoul, South Korea.
  • Madelaine J; Pulmonology Department, Caen University Hospital, Caen, France.
  • Molinier O; Pneumology Department, Hospital Center, Le Mans, France.
  • Özgüroglu M; Department of Internal Medicine, Division of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Rodríguez Abreu D; Department of Medical Oncology, Gran Canaria University Hospital, Las Palmas de Gran Canaria, Spain.
  • Adeniji A; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
  • Lorence RM; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
  • Voccia I; Boehringer Ingelheim Canada, Burlington, ON, Canada.
  • Chisamore MJ; Merck & Co., Inc, Rahway, NJ, USA.
  • Riess JW; UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Lung Cancer ; 166: 107-113, 2022 04.
Article en En | MEDLINE | ID: mdl-35257949
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Neoplasias Pulmonares Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Escamosas / Neoplasias Pulmonares Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article